<DOC>
	<DOC>NCT01755403</DOC>
	<brief_summary>o study population pharmacokinetics in Benznidazole-treated adult patients with Chronic Chagas Disease to get information to optimize drug doses.</brief_summary>
	<brief_title>Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease</brief_title>
	<detailed_description />
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Benzonidazole</mesh_term>
	<criteria>Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive serological tests. Patients with Chronic Chagas Disease who are going to start treatment with Benznidazole. Any gender. All the participants must agree to participate in the study and must sign the informed consent. Patients younger than 18. Patients with previous hypersensitivity to Benznidazole. Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need, primary immunodeficiency, or any other. Hepatic dysfunction Renal dysfunction: serum creatinin higher than 3 mg/dl. Pregnancy or lactation. Low adhesion to treatment or checkup. Impossibility of followup. Severe adverse reaction to Benznidazole. Any other situation that could be risky for the patient.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>